Menu
← Oncology Approval Tracker
FDA DECISION ·
Revuforj
revumenib · Syndax Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults and children age 1 year or older with relapsed or refractory AML with a susceptible NPM1 mutation and no satisfactory alternative treatment options.
LAMPGEN ANALYSIS
Why it matters
This approval extends menin inhibition from KMT2A-rearranged acute leukemia to susceptible NPM1-mutated AML.
What research teams should watch
Set up rapid molecular testing at relapse and align early differentiation syndrome and ECG monitoring across sites.
PRIMARY RECORDS